Kantarjian et al53 assessed the efficacy and safety of dasatinib, as when compared with imatinib, for the primary-line treatment of CML-CP. 5 hundred and nineteen people with recently diagnosed CML-CP ended up randomly assigned to get dasatinib in a dose of one hundred mg when everyday (259 clients) or imatinib https://sarolaner76543.qowap.com/88341441/top-lji308-secrets